@jeromeleonard5@BioValues Yeah, they've been very shady. They used the July R&D day to 'present' mono data for the CTLA-4, then never mentioned that data and buried it in a press release summarizing the event later that evening (ORR 0%)
@jeromeleonard5@BioValues Wondered the same thing about the n. Where are all the other patients? Also, they've been saying the same thing about partnering for a full year now. So far, it appears that nobody is impressed enough to bite.
@FreeloadFreddy Lol. I bought at 1.80 and have been playing with the house's money for months.
Why do you care? What kind of person takes pleasure in others' losses?
Have you tried porn?
@bguan69 @NetMelc@Zerosumgame33@xEBITDA Yeah, the story is still 'We got the loan.... BUT we won't actually get it for another quarter at least and we have to raise 100m in the meantime.
@bkfichter Many expect them to announce (potentially big) new orders/customers now that the loan is in. For example, Eos sliding into position to be a leading LDES supplier for the state of California...
Seaport Global Analyst Reiterates Buy
Tom Curran, analyst at Seaport Global, reiterates Buy Rating on $ACDC with a price target of $ 30. Is $ACDC on your radar?....Check this out.
https://t.co/pUKdNxPa6N
$ACDC #ACDC#Industrial Goods #stockstowatch#StocksToTrade
@x_times_1 @EtcheFabien Lithium remains key for EVs (owing to density issues), which are only just beginning to take off. Something to keep in mind for any future demand/price projections. You need lithium in cars, whereas in BESS you have more options.
@duedillengence@ReidoFinancial I think Stifel's read has some of your answers. Company raises 20% itself to get started, DOE money will come as new lines go up to help scale. https://t.co/Lm1NKVj8tA